Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Basal Cell 2Basal Cell Nevus Syndrome 2

Interventions

HhAntag691 25Imiquimod 12Biopsy 12sonidegib 11Aminolevulinic Acid 9cemiplimab 8Photochemotherapy 8Nivolumab 8methyl 5-aminolevulinate 7Mohs Surgery 71-phenyl-3,3-dimethyltriazene 7Tomography, Optical Coherence 6Surgical Procedures, Operative 6Specimen Handling 5Radiotherapy 5Itraconazole 5pembrolizumab 4daromun 4Microscopy, Confocal 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Curettage 4Standard of Care 3Niacinamide 3IPI-926 3CTLA-4 Antigen 33-ingenyl angelate 3tazarotene 2talimogene laherparepvec 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Basal Cell × Drug Evaluation × Dermatologic × Clear all
NCT02762084 2020-07-23

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

PellePharm, Inc.

Phase 2 Completed
17 enrolled 22 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02828111 2019-01-08

BCC

PellePharm, Inc.

Phase 2 Completed
36 enrolled 17 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡